French professor faces disciplinary case over hydroxychloroquine claims
Didier Raoult stands accused of touting drug as a coronavirus treatment without evidenceA French professor who touts the anti-malaria drug hydroxychloroquine as a coronavirus treatment – without evidence, scientists say – will appear before a disciplinary panel charged with ethics breaches, an order of doctors has said.Marseille-basedDidier Raoult stands accused by his peers of spreading false information about the benefits of the drug. His promotion of hydroxychloroquine wastaken up by the US and Brazilian presidents, Donald Trump and Jair Bolsonaro, who trumpeted its unproven benefits in a way critics say put people ...
Source: Guardian Unlimited Science - November 12, 2020 Category: Science Authors: Agence France-Presse in Marseille Tags: France Coronavirus Europe Infectious diseases Science Medical research World news Health Drugs Microbiology Source Type: news
Study: Hydroxychloroquine no better than placebo for hospitalized COVID-19 patients
COVID-19 patients treated with hydroxychloroquine showed no signs of significant improvement in " clinical status " compared with those given a placebo, a study published Monday by JAMA found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - November 9, 2020 Category: Consumer Health News Source Type: news
Joe Biden and Kamala Harris Announce Their COVID-19 Advisory Board
On Nov. 9, the Biden-Harris transition team announced the members of its COVID-19 advisory board, and met with them for several hours in a virtual conference before President-elect Joe Biden made remarks stressing the importance of mask wearing as a continued “weapon” in the fight against COVID-19.
“As we work toward a safe and effective vaccine, the single most effective way to stop the spread of COVID-19: wear a mask,” Biden said, as he held up his own mask. “The head of the CDC [Centers for Disease Control] warned this fall that for the foreseeable future, a mask remains the most potent wea...
Source: TIME: Health - November 9, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Hydroxychloroquine does not treat COVID-19, NIH 'formally' declares
After 14 days, more hospitalized coronavirus patients treated with hydroxychloroquine had died than had those who got a placebo. By 28 days, rates were about the same, the NIH trial found. (Source: the Mail online | Health)
Source: the Mail online | Health - November 9, 2020 Category: Consumer Health News Source Type: news
Hydroxychloroquine does not benefit adults hospitalized with COVID-19
The trial began after lab studies and preliminary reports suggested that hydroxychloroquine might have promise in treating SARS-CoV-2. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - November 9, 2020 Category: American Health Source Type: news
Effect of hydroxychloroquine on clinical status
(JAMA Network) This randomized trial compares the effects of hydroxychloroquine versus placebo on patients' clinical status at 14 days (home, requiring noninvasive or invasive ventilation or extracorporeal membrane oxygenation, hospitalized, died) among adults hospitalized with COVID-19. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 9, 2020 Category: Infectious Diseases Source Type: news
Chloroquine Prescribing Patterns for COVID-19 by Specialty Chloroquine Prescribing Patterns for COVID-19 by Specialty
This report reveals that new prescriptions by specialists who don ' t typically prescribe hydroxychloroquine or chloroquine increased nearly 80-fold during the initial months of the COVID-19 pandemic.Morbidity & Mortality Weekly Report (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 6, 2020 Category: Consumer Health News Tags: Public Health & Prevention Journal Article Source Type: news
COVID-19-Related HCQ Shortages Affected Rheum Patients Worldwide COVID-19-Related HCQ Shortages Affected Rheum Patients Worldwide
Supplies were diverted for COVID when hydroxychloroquine was hyped, without good evidence, as a treatment. In some parts of the world more than 1 in 4 with autoimmune diseases could not get medicines.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 6, 2020 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news
Doc Who Used Hydroxychloroquine Met Standard of Care; More Doc Who Used Hydroxychloroquine Met Standard of Care; More
Doctor who treated COVID patients met standard of care, officials say; VA settles multiple wrongful-death suits; attorney charged with trying to scam hospital system.Medscape Business of Medicine (Source: Medscape Business of Medicine Headlines)
Source: Medscape Business of Medicine Headlines - November 3, 2020 Category: Pharmaceuticals Tags: Family Medicine/Primary Care News Source Type: news
States Want to Approve COVID-19 Vaccines Themselves. Will That Lead to More Trust —Or Less?
Getting a COVID-19 vaccine—and fast—has been a main focus in the fight against the coronavirus. But when a vaccine is ultimately made available to the American public, California Governor Gavin Newsom said at a press conference last week, another factor will come into play: what he called the “speed of trust.”
“You have to have confidence in the efficacy of the vaccine, confidence that we’re not rushing to judgment in terms of its distribution and its accessibility,” said Newsom. His comments came while announcing that his state is convening a scientific review panel to double-chec...
Source: TIME: Health - October 30, 2020 Category: Consumer Health News Authors: Tara Law Tags: Uncategorized COVID-19 Source Type: news
U.S. COVID-19 Cases Are Skyrocketing, But Deaths Are Flat —So Far. These 5 Charts Explain Why
In just the last two weeks, the global daily tally for new COVID-19 cases has jumped more than 30%, according to TIME’s coronavirus tracker, which compiles data from Johns Hopkins University. The steep upward trend is driven by viral waves in Europe and the United States that started in August and mid-September, respectively. On Oct. 23, the daily case count in the U.S. reached a new record high, suggesting that this wave will be worse than the one that swept the country over the summer.
But despite this rapid uptick in cases, the daily death count in the U.S. is not yet rising at the same rate, and remains at lower ...
Source: TIME: Health - October 26, 2020 Category: Consumer Health News Authors: Emily Barone Tags: Uncategorized COVID-19 UnitedWeRise20Disaster Source Type: news
U of M trial shows hydroxychloroquine does not prevent COVID-19 in health care workers
(University of Minnesota) University of Minnesota Medical School researchers found that taking hydroxychloroquine once or twice weekly did not prevent the development of COVID-19 in health care workers better than the placebo. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - October 21, 2020 Category: Infectious Diseases Source Type: news
What the Conflicting Results on Promising COVID-19 Drug Remdesivir Really Mean
Treating any infectious disease is a high wire act—doctors must balance the risks and benefits of therapies with the risks of the disease. And those stakes are even higher for a new disease that doesn’t yet have a playbook for physicians to follow.
This summer, the U.S. Food and Drug Administration gave the drug remdesivir emergency use authorization for treating any patients hospitalized with COVID-19. But on Oct.15, researchers working on the World Health Organization’s (WHO) Solidarity trial published a preliminary report showing that nearly 3,000 people receiving the treatment were not more likely to ...
Source: TIME: Health - October 19, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Study finds remdesivir, hydroxychloroquine have 'little' impact on mortality in COVID-19 patients
A clinical trial conducted by the World Health Organization found that Gilead Sciences Inc.'s remdesivir, hydroxychloroquine, AbbVie's... (Source: Reuters: Health)
Source: Reuters: Health - October 16, 2020 Category: Consumer Health News Source Type: news
Coronavirus: Remdesivir has 'little effect' on death risks, says WHO
The WHO's 11,266-person trial found no significant reduction in mortality risks among hospitalized COVID-19 patients treated with remdesivir, lopinavir, interferon or hydroxychloroquine (Source: the Mail online | Health)
Source: the Mail online | Health - October 15, 2020 Category: Consumer Health News Source Type: news
